Bringing the Oncology Community Together

Treating Low-Risk HER2-Positive Breast Cancer

Panelists: Kimberly L. Blackwell, MD, Duke; Adam M. Brufsky, MD, PhD, University of Pittsburgh;
Joyce A. O’Shaughnessy, MD, US Oncology; Mark D. Pegram, MD, Stanford; Hope S. Rugo, MD, UCSF;
Denise A. Yardley, MD, Sarah Cannon
Published Online: Thursday, January 23, 2014
For High-Definition, Click
The regimens utilized to treat HER2-positive breast cancer continue to evolve as new therapies gain approval. By and large, HER2 status is being determined at a much earlier stage. Moreover, the increased efficacy of HER2-targeted therapies represents the potential to alter accompanying chemotherapeutics without significantly changing outcomes.

In the phase II TRYPHAENA study, 225 patients with HER2-positive early-stage breast cancer were treated with TCH (Taxotere, Carboplatin, Herceptin) plus pertuzumab or an anthracycline-based chemotherapy with or without pertuzumab and trastuzumab followed by pertuzumab, trastuzumab, and docetaxel. In general, the pathologic complete response (pCR) rates with these treatments were similar, Joyce A. O’Shaughnessy, MD, states. In fact, the pCR with TCH plus pertuzumab was 63.6% compared with the anthracycline-based regimens, which had a pCR rate around 55%. As a result, O’Shaughnessy prefers to administer anthracycline free regimens.

The primary endpoint of the TRYPHAENA study was cardiac safety, points out Hope S. Rugo, MD. Along with the secondary efficacy findings, the TCH plus pertuzumab regimen also demonstrated a marked reduction in toxicity, making it an appealing option, Rugo believes.

It is reasonable to present both options to patients, believes Mark D. Pegram, MD. Moreover, studies have shown that carboplatin can be omitted from the TCH regimen without significantly altering outcomes, even without the addition of an anthracycline, Pegram says.

For patients who do not tolerate docetaxel/carboplatin, Rugo recommends a switch to weekly paclitaxel with low-dose carboplatin. In a single-arm phase II study, weekly paclitaxel with trastuzumab was explored as a treatment for patients with low-risk HER2-positive breast cancer. This study demonstrated impressive findings, Rugo states. A randomized follow-up trial will compare paclitaxel plus trastuzumab to T-DM1.

View More From This Discussion
Episode 1 Overview of HER2-Targeted Therapies in Breast Cancer
Episode 2 Treating Low-Risk HER2-Positive Breast Cancer
Episode 3 Frontline Pertuzumab for Metastatic Breast Cancer
Episode 4 PIK3CA Mutations in HER2-Positive Breast Cancer
Episode 5 T-DM1 in HER2-Positive Metastatic Breast Cancer
Episode 6 Recommendations for Optimal HER2 Testing in Breast Cancer
Episode 7 Role of Lapatinib in HER2-Positive Breast Cancer
Episode 8 Novel Drug Development in Breast Cancer
Episode 9 Phase III Clinical Trials in HER2-Positive Breast Cancer
Episode 10 Case Study: HER2-Positive Oligometastatic Breast Cancer
Expert Panelists
Dr Adam Brufsky

Adam M. Brufsky, MD, PhD

Professor of Medicine, University of Pittsburgh
Medical Director of the Women’s Cancer Center at Magee-Womens Hospital of UPMC
and the University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Kimberly L. Blackwell, MD

Professor of Medicine
Assistant Professor in Radiation Oncology
Duke Cancer Institute
Durham, North Carolina

Joyce A. O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Dallas, Texas

Mark D. Pegram, MD

Professor of Medicine (Oncology)
Stanford University Medical Center;
Susy Yuan-Huey Hung Professor;
Associate Director of Clinical Research and Director, Breast Cancer Program, Stanford Cancer Institute, Stanford, California

Hope S. Rugo, MD

Professor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center,
San Francisco, California

Denise A. Yardley, MD

Senior Investigator, Breast Cancer Research
Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.